Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7974503 | 0.93 | HSD11B1 (0.54) | HSD11B1 | |
| SCHEMBL12671081 | 0.92 | HSD11B1 (0.53) | HSD11B1 | |
| SCHEMBL12671073 | 0.87 | HSD11B1 (0.53) | HSD11B1 | |
| SCHEMBL12671301 | 0.85 | HSD11B1 (0.39) | HSD11B1 | |
| SCHEMBL12671259 | 0.84 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL7991823 | 0.83 | HSD11B1 (0.46) | HSD11B1 | |
| SCHEMBL12671279 | 0.82 | HSD11B1 (0.55) | HSD11B1 | |
| SCHEMBL7970939 | 0.82 | HSD11B1 (0.43) | HSD11B1 | |
| SCHEMBL29306610 | 0.82 | HSD11B1 (0.45) | HSD11B1 | |
| SCHEMBL12671092 | 0.81 | HSD11B1 (0.46) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327474-A1 | THERAPEUTIC AGENT FOR PAIN | ASTELLAS PHARMA INC. (JP) | 2017-11-16 | — | — | US | claimed |
| US-9765040-B2 | Therapeutic agent for pain | ASTELLAS PHARMA INC. (JP) | 2017-09-19 | — | — | US | claimed |
| EP-2614824-B1 | TRIAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN AND FIBROMYALGIA | ASTELLAS PHARMA INC (JP) | 2015-03-11 | — | — | EP | claimed |
| EP-2614824-A1 | THERAPEUTIC AGENT FOR PAIN | Astellas Pharma Inc. (JP) | 2013-07-17 | — | — | EP | claimed |
| US-20130165491-A1 | THERAPEUTIC AGENT FOR PAIN | ASTELLAS PHARMA INC. (JP) | 2013-06-27 | — | — | US | claimed |
| US-20170327474-A1 | THERAPEUTIC AGENT FOR PAIN | ASTELLAS PHARMA INC. (JP) | 2017-11-16 | — | — | US | disclosed |
| US-20170327474-A1 | THERAPEUTIC AGENT FOR PAIN | ASTELLAS PHARMA INC. (JP) | 2017-11-16 | — | — | US | disclosed |
| US-20170327474-A1 | THERAPEUTIC AGENT FOR PAIN | ASTELLAS PHARMA INC. (JP) | 2017-11-16 | — | — | US | disclosed |
| US-9765040-B2 | Therapeutic agent for pain | ASTELLAS PHARMA INC. (JP) | 2017-09-19 | — | — | US | disclosed |
| US-9765040-B2 | Therapeutic agent for pain | ASTELLAS PHARMA INC. (JP) | 2017-09-19 | — | — | US | disclosed |
| US-9765040-B2 | Therapeutic agent for pain | ASTELLAS PHARMA INC. (JP) | 2017-09-19 | — | — | US | disclosed |
| EP-2614824-B1 | TRIAZOLE DERIVATIVE FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN AND FIBROMYALGIA | ASTELLAS PHARMA INC (JP) | 2015-03-11 | — | — | EP | disclosed |
| US-20130165491-A1 | THERAPEUTIC AGENT FOR PAIN | ASTELLAS PHARMA INC. (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20130165491-A1 | THERAPEUTIC AGENT FOR PAIN | ASTELLAS PHARMA INC. (JP) | 2013-06-27 | — | — | US | disclosed |
| US-20130165491-A1 | THERAPEUTIC AGENT FOR PAIN | ASTELLAS PHARMA INC. (JP) | 2013-06-27 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-8377923-B2 | Triazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2013-02-19 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-05-05 | — | — | US | disclosed |
| WO-2010001946-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | アステラス製薬株式会社 (JP) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165491-A1 | THERAPEUTIC AGENT FOR PAIN | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885 |
| US-20170327474-A1 | THERAPEUTIC AGENT FOR PAIN | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885 |
| US-20110105460-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | HSD11B1, HSD11B2, HSD3B1 | HSD11B1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.